Real-world evidence (RWE) is transforming pharma pricing and market access (P&MA) strategies - but are you leveraging its full potential? As healthcare systems increasingly demand robust, real-world data to support pricing and reimbursement decisions, understanding how to strategically employ RWE is more critical than ever.
Join the next episode of the Simon-Kucher Better Market Access webinar series for exclusive insights from our latest industry benchmarking study on RWE and academic collaboration.
This webinar will cover:
- How RWE is employed across the drug lifecycle, from clinical development to market entry and post-launch applications
- The clinical uncertainties RWE can help address and its role in supporting both short- and long-term strategic P&MA objectives
- Insights into how key European HTA bodies and payer organizations assess and incorporate RWE in health technology assessments and price negotiations
- Key drivers and barriers influencing RWE acceptance across supranational, national, and regional HTA and payer bodies in major markets
- Best practices for identifying high-impact RWE opportunities early by leveraging internal capabilities and external academic collaborations
This event is free of charge. Don’t miss the chance to gain a deeper understanding of how industry leaders strategically leverage RWE to optimize P&MA outcomes and navigate the evolving evidentiary landscape.
Event Details:
To accommodate different time zones, we are offering two identical sessions:
• March 11, 2025 | 10:30 - 11:30 a.m. CET | 1:30 - 2:30 p.m. GMT+4
• March 13, 2025 | 5:00 - 6:00 p.m. CET | 12:00 - 1:00 p.m. EDT
